

TJW


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/61502	
Application Number 10/717,148	Filing Date November 18, 2003	Examiner To be assigned	Art Unit 1615
Invention Title CRYSTALLIZATION METHOD FOR PURIFICATION OF CALCIPOTRIENE		Inventor(s) SCHWARTZ, et al.	

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 22313-1450 on:

Date: 5/17/04

Signature: 

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed.
3. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.

Dated:

May 19, 2004

By:


John B. Starr, Jr. (Reg. No. 44,474)

KENYON & KENYON
One Broadway
New York, New York 10004
(212) 425-7200 (telephone)



**INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT
PTO-1449**

ATTY. DOCKET NO. 1662/61502	SERIAL NO. 10/717,148
--------------------------------	--------------------------

APPLICANT SCHWARTZ et al.

FILING DATE November 18, 2003	GROUP 1615
----------------------------------	---------------

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,292,727 A	March 8, 1994	Godtfredsen			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03 060094	July 24, 2003	Europe				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	PCT International Search Report - PCT/US03/37138
	Martin J. Caverley, "Synthesis of MC 903, a biologically active vitamin D metabolite analogue", Tetrahedron, vol. 43, no. 20, 1987, pgs. 4609-4616.
	Caverley, M. J. and Bretting, C., "1-alpha-24S-dihydroxy-26, 27-cyclo-22-yne-vitamin D3: the side chain triple bond analogue of MC 903 (calcipotriol)", Bioorganic and Medicinal Chemistry Letters, vol. 3, n. 9, 1993, pgs. 1841-1844.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	